Table 8.
Summary of the total pharmaceutical expense of antineoplastic drugs and supportive therapy for each study year.
| Treatment | Study Year | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Total | |
| Antineoplastic agents | |||||||||||
| Intravenous | €6,565,263 | €4,464,740 | €4,695,722 | €4,436,132 | €5,770,959 | €7,596,964 | €9,769,375 | €9,475,022 | €11,252,776 | €12,666.317 | €76,693,270 |
| Oral | €2,579,163 | €3,271,684 | €2,853,205 | €2,437,685 | €3,302,873 | €4,346,928 | €4,581,945 | €4,990,955 | €6,723,301 | €8,615,087 | €43,702,826 |
| Total antineoplastic agents | €9,144,426 | €7,736,424 | €7,548,927 | €6,873,817 | €9,073,832 | €11,943,892 | €14,351,320 | €14,465,977 | €17,976,077 | €21,281,404 | €120,396,096 |
| Supportive therapy | |||||||||||
| Antiemetics | €252,598 | €149,146 | €80,865 | €102,012 | €97,625 | €86,005 | €110,673 | €73,862 | €59,853 | €59,115 | €1,071,755 |
| Erythropoietins | €182,782 | €261,803 | €220,567 | €132,728 | €105,447 | €140,141 | €126,266 | €142,798 | €88,147 | €61,093 | €1,461,773 |
| G-CSF factors | €582,602 | €336,822 | €377,331 | €92,995 | €139,564 | €199,158 | €207,005 | €69,604 | €32,554 | €43,919 | €2,081,554 |
| Bone resorption inhibitors | - | €195,329 | €224,430 | €120,942 | €36,513 | €61,983 | €121,613 | €116,241 | €116,079 | €143,697 | €1,136,827 |
| Total Supportive therapy | €1,017,982 | €943,100 | €903,193 | €448,677 | €379,149 | €487,287 | €565,557 | €402,505 | €296,634 | €307,825 | €5,751,910 |
| TOTAL | €10,162,408 | €8,679,524 | €8,452,120 | €7,322,494 | €9,452,981 | €12,431,179 | €14,916,877 | €14,868,482 | €18,272,711 | €21,589,229 | €126,148,006 |